Advertisement

Thalidomide induces apoptosis in undifferentiated human induced pluripotent stem cells

  • Saoko Tachikawa
  • Toshinobu Nishimura
  • Hiromitsu Nakauchi
  • Kiyoshi OhnumaEmail author
Article

Abstract

Thalidomide, which was formerly available commercially to control the symptoms of morning sickness, is a strong teratogen that causes fetal abnormalities. However, the mechanism of thalidomide teratogenicity is not fully understood; thalidomide toxicity is not apparent in rodents, and the use of human embryos is ethically and technically untenable. In this study, we designed an experimental system featuring human-induced pluripotent stem cells (hiPSCs) to investigate the effects of thalidomide. These cells exhibit the same characteristics as those of epiblasts originating from implanted fertilized ova, which give rise to the fetus. Therefore, theoretically, thalidomide exposure during hiPSC differentiation is equivalent to that in the human fetus. We examined the effects of thalidomide on undifferentiated hiPSCs and early-differentiated hiPSCs cultured in media containing bone morphogenetic protein-4, which correspond, respectively, to epiblast (future fetus) and trophoblast (future extra-embryonic tissue). We found that only the number of undifferentiated cells was reduced. In undifferentiated cells, application of thalidomide increased the number of apoptotic and dead cells at day 2 but not day 4. Application of thalidomide did not affect the cell cycle. Furthermore, immunostaining and flow cytometric analysis revealed that thalidomide exposure had no effect on the expression of specific markers of undifferentiated and early trophectodermal differentiated cells. These results suggest that the effect of thalidomide was successfully detected in our experimental system and that thalidomide eliminated a subpopulation of undifferentiated hiPSCs. This study may help to elucidate the mechanisms underlying thalidomide teratogenicity and reveal potential strategies for safely prescribing this drug to pregnant women.

Keywords

Thalidomide Human induced pluripotent cells Teratogenicity 

Notes

Acknowledgments

This work was supported in part by grants from the Ministry of Health, Labour, and Welfare of Japan, the Japan Agency for Medical Research and Development (AMED) (to K.O.), and the Foundation for Applied Research and Technological Uniqueness at Nagaoka University of Technology (to S.T.). The funding bodies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author contributions

S.T. and K.O. designed the project. S.T. performed all experiments. T.N. and H.N. provided a hiPS clone and helpful feedback on the manuscript. S.T. and K.O. wrote the manuscript and all authors reviewed the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing financial interests.

Supplementary material

11626_2017_192_MOESM1_ESM.docx (155 kb)
Supplementary Fig. 1 (DOCX 155 kb)

References

  1. Aikawa N, Kunisato A, Nagao K, Kusaka H, Takaba K, Ohgami K (2014) Detection of thalidomide embryotoxicity by in vitro embryotoxicity testing based on human iPS cells. J Pharmacol Sci 124:201–207CrossRefPubMedGoogle Scholar
  2. Amita M, Adachi K, Alexenko AP, Sinha S, Schust DJ, Schulz LC, Roberts RM, Ezashi T (2013) Complete and unidirectional conversion of human embryonic stem cells to trophoblast by BMP4. Proc Natl Acad Sci U S A 110:E1212–E1221CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ando M, Nishimura T, Yamazaki S, Yamaguchi T, Kawana-Tachikawa A, Hayama T, Nakauchi Y, Ando J, Ota Y, Takahashi S, Nishimura K, Ohtaka M, Nakanishi M, Miles JJ, Burrows SR, Brenner MK, Nakauchi H (2015) A safeguard system for induced pluripotent stem cell-derived rejuvenated T cell therapy. Stem Cell Rep 5:597–608CrossRefGoogle Scholar
  4. Chen G, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, Probasco MD, Smuga-Otto K, Howden SE, Diol NR, Propson NE, Wagner R, Lee GO, Antosiewicz-Bourget J, Teng JM, Thomson JA (2011) Chemically defined conditions for human iPSC derivation and culture. Nat Methods 8:424–429CrossRefPubMedPubMedCentralGoogle Scholar
  5. Debock CA, Peters A (1963) Effect of thalidomide on the development of the chick embryo. Nature 199:1204–1206CrossRefPubMedGoogle Scholar
  6. Franks ME, Macpherson GR, Figg WD (2004) Thalidomide. Lancet 363:1802–1811CrossRefPubMedGoogle Scholar
  7. Fratta ID, Sigg EB, Maiorana K (1965) Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. Toxicol Appl Pharmacol 7:268–286CrossRefPubMedGoogle Scholar
  8. Furue MK, Na J, Jackson JP, Okamoto T, Jones M, Baker D, Hata R, Moore HD, Sato JD, Andrews PW (2008) Heparin promotes the growth of human embryonic stem cells in a defined serum-free medium. Proc Natl Acad Sci U S A 105:13409–13414CrossRefPubMedPubMedCentralGoogle Scholar
  9. Guo CW, Kawakatsu M, Idemitsu M, Urata Y, Goto S, Ono Y, Hamano K, Li TS (2013) Culture under low physiological oxygen conditions improves the stemness and quality of induced pluripotent stem cells. J Cell Physiol 228:2159–2166CrossRefPubMedGoogle Scholar
  10. Hayashi Y, Chan T, Warashina M, Fukuda M, Ariizumi T, Okabayashi K, Takayama N, Otsu M, Eto K, Furue MK, Michiue T, Ohnuma K, Nakauchi H, Asashima M (2010) Reduction of N-glycolylneuraminic acid in human induced pluripotent stem cells generated or cultured under feeder- and serum-free defined conditions. PLoS One 5:e14099CrossRefPubMedPubMedCentralGoogle Scholar
  11. Hughes CS, Postovit LM, Lajoie GA (2010) Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics 10:1886–1890CrossRefPubMedGoogle Scholar
  12. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science (New York, NY) 327:1345–1350CrossRefGoogle Scholar
  13. Jackson SA, Schiesser J, Stanley EG, Elefanty AG (2010) Differentiating embryonic stem cells pass through 'temporal windows' that mark responsiveness to exogenous and paracrine mesendoderm inducing signals. PLoS One 5:e10706CrossRefPubMedPubMedCentralGoogle Scholar
  14. Kameoka S, Babiarz J, Kolaja K, Chiao E (2014) A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci : Off J Soc Toxicol 137:76–90CrossRefGoogle Scholar
  15. Knobloch J, Ruther U (2008) Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle 7:1121–1127CrossRefPubMedGoogle Scholar
  16. Knobloch J, Shaughnessy JD, Ruther U (2007) Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 21(7):1410–1421Google Scholar
  17. Kumagai A, Suga M, Yanagihara K, Itoh Y, Takemori H, Furue MK (2016) A simple method for labeling human embryonic stem cells destined to lose undifferentiated potency. Stem Cells Transl Med 5:275–281CrossRefPubMedPubMedCentralGoogle Scholar
  18. Mayshar Y, Yanuka O, Benvenisty N (2011) Teratogen screening using transcriptome profiling of differentiating human embryonic stem cells. J Cell Mol Med 15:1393–1401CrossRefPubMedGoogle Scholar
  19. Meganathan K, Jagtap S, Wagh V, Winkler J, Gaspar JA, Hildebrand D, Trusch M, Lehmann K, Hescheler J, Schluter H, Sachinidis A (2012) Identification of thalidomide-specific transcriptomics and proteomics signatures during differentiation of human embryonic stem cells. PLoS One 7:e44228CrossRefPubMedPubMedCentralGoogle Scholar
  20. Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39:1489–1499CrossRefPubMedGoogle Scholar
  21. Miller MT, Stromland K (1999) Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 60:306–321CrossRefPubMedGoogle Scholar
  22. Moore KL, Persaud TVN, Torchia MG (2015) The developing human Clinically oriented embryology, 10th edition. Elsevier Health Sciences, Netherlands AmsterdamGoogle Scholar
  23. Nichols J, Smith A (2009) Naive and primed pluripotent states. Cell Stem Cell 4:487–492CrossRefPubMedGoogle Scholar
  24. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, Nakayama-Hosoya K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H (2013) Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12:114–126CrossRefPubMedGoogle Scholar
  25. Nowack E (1965) The sensitive phase in thalidomide embryopathy. Humangenetik 1:516–536CrossRefPubMedGoogle Scholar
  26. Ohgushi M, Matsumura M, Eiraku M, Murakami K, Aramaki T, Nishiyama A, Muguruma K, Nakano T, Suga H, Ueno M, Ishizaki T, Suemori H, Narumiya S, Niwa H, Sasai Y (2010) Molecular pathway and cell state responsible for dissociation-induced apoptosis in human pluripotent stem cells. Cell Stem Cell 7:225–239CrossRefPubMedGoogle Scholar
  27. Ohnuma K, Fujiki A, Yanagihara K, Tachikawa S, Hayashi Y, Ito Y, Onuma Y, Chan T, Michiue T, Furue MK, Asashima M (2014) Enzyme-free passage of human pluripotent stem cells by controlling divalent cations. Sci Rep 4:4646CrossRefPubMedPubMedCentralGoogle Scholar
  28. Orkin RW, Gehron P, McGoodwin EB, Martin GR, Valentine T, Swarm R (1977) A murine tumor producing a matrix of basement membrane. J Exp Med 145:204–220CrossRefPubMedGoogle Scholar
  29. Parman T, Wiley MJ, Wells PG (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582–585Google Scholar
  30. Qin XY, Akanuma H, Wei F, Nagano R, Zeng Q, Imanishi S, Ohsako S, Yoshinaga J, Yonemoto J, Tanokura M, Sone H (2012) Effect of low-dose thalidomide on dopaminergic neuronal differentiation of human neural progenitor cells: a combined study of metabolomics and morphological analysis. Neurotoxicology 33:1375–1380CrossRefPubMedGoogle Scholar
  31. Schardein JL (2000) Chemically induced birth defects, third edition. Informa Healthcare, New York LondonGoogle Scholar
  32. Seiler AE, Spielmann H (2011) The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat Protoc 6:961–978CrossRefPubMedGoogle Scholar
  33. Sheskin J (1965) Thalidomide in the treatment of LEPRA reactions. Clin Pharmacol Ther 6:303–306CrossRefPubMedGoogle Scholar
  34. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571CrossRefPubMedGoogle Scholar
  35. Syme MR, Paxton JW, Keelan JA (2004) Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43:487–514CrossRefPubMedGoogle Scholar
  36. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872CrossRefPubMedGoogle Scholar
  37. Therapontos C, Erskine L, Gardner ER, Figg WD, Vargesson N (2009) Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A 106:8573–8578CrossRefPubMedPubMedCentralGoogle Scholar
  38. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science (New York, NY) 282:1145–1147CrossRefGoogle Scholar
  39. Vukicevic S, Kleinman HK, Luyten FP, Roberts AB, Roche NS, Reddi AH (1992) Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp Cell Res 202:1–8CrossRefPubMedGoogle Scholar
  40. Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, Takahashi JB, Nishikawa S, Nishikawa S, Muguruma K, Sasai Y (2007) A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 25:681–686CrossRefPubMedGoogle Scholar
  41. Xu RH, Chen X, Li DS, Li R, Addicks GC, Glennon C, Zwaka TP, Thomson JA (2002) BMP4 initiates human embryonic stem cell differentiation to trophoblast. Nat Biotechnol 20:1261–1264CrossRefPubMedGoogle Scholar
  42. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S (2009) Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 5:237–241CrossRefPubMedGoogle Scholar
  43. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science (New York, NY) 318:1917–1920CrossRefGoogle Scholar
  44. Zeldis JB, Williams BA, Thomas SD, Elsayed ME (1999) S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319–330CrossRefPubMedGoogle Scholar

Copyright information

© The Society for In Vitro Biology 2017

Authors and Affiliations

  1. 1.Department of BioengineeringNagaoka University of TechnologyNiigataJapan
  2. 2.Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical ScienceUniversity of TokyoTokyoJapan
  3. 3.Institute for Stem Cell Biology and Regenerative MedicineStanford University School of MedicineStanfordUSA
  4. 4.Department of Science of Technology InnovationNagaoka University of TechnologyNiigataJapan

Personalised recommendations